This application describes embodiments of apparatuses, methods, and systems for the treatment of wounds, specifically to aid in the closure of large wounds.
Acute compartment syndrome occurs when tissue pressure within a closed muscle compartment exceeds the perfusion pressure and it most commonly occurs in compartments in the leg or arm. Fasciotomy is a surgical procedure to treat acute compartment syndrome. Fasciotomy consists of one or more fascial incisions to permit decompression of the compartments, and as such, a large wound may be created onto the patient. Closure of this wound, while minimizing the risk of secondary infections and other complications, and after the underlying edema has subsided, then becomes a priority. Other large or incisional wounds, either as a result of surgery, trauma, or other conditions, may also require closure. Wound dehiscence of existing wounds is another complication that may arise, possibly due to incomplete underlying fascial closure, or secondary factors such as infection.
The treatment of open or chronic wounds by means of applying negative pressure to the site of the wound, where the wounds are too large to spontaneously close or otherwise fail to heal is well known in the art. Negative pressure, in many cases, can improve the rate of healing while also removing exudates and other deleterious substances from the wound. Negative pressure wound treatment systems currently known in the art commonly involve placing a cover that is impermeable to liquids over the wound, using various mechanisms to seal the cover to the tissue of the patient surrounding the wound, and connecting a source of negative pressure (such as a vacuum pump) to the cover whereby an area of negative pressure is created under the cover in the area of the wound.
However, existing negative pressure treatment systems, while permitting eventual wound closure, still require lengthy closure times. Although these may be combined with other tissue securement means, such as sutures, there is also a risk that underlying muscular and fascial tissue is not appropriately reapproximated so as to permit complete wound closure. Further, when foam or other wound fillers are inserted into the wound, the application of negative pressure to the wound and the foam may cause atmospheric pressure to bear down onto the wound, compressing the foam downward and outward against the margins of the wound. This downward compression of the wound filler slows the healing process and slows or prevents the joining of wound margins. Additionally, inflammation of the fascia in the form of certain types of fasciitis can lead to rapid and excessive tissue loss, potentially meriting the need for more advanced negative pressure treatment systems. Accordingly, there is a need to provide for an improved apparatus, method, and system for the treatment and closure of wounds.
Certain disclosed embodiments relate to negative pressure wound closure devices, methods, and systems that facilitate closure of a wound. It will be understood by one of skill in the art that the wounds described may encompass any wound, and are not limited to a particular location or type of wound. Further, it will be understood by one of skill of art that application of the devices, methods, and systems described herein are not limited to the closure of wound or any other particular use. The devices, methods, and systems may operate to reduce the need for repetitive replacement of wound filler material currently employed and can advance the rate of healing. The devices, methods, and systems may be simultaneously used with negative pressure to remove wound fluids.
In some embodiments, a wound closure device may comprise a collapsible sheet configured to be placed over a wound. The collapsible sheet comprises:
In some embodiments, at least some of the cells may be inflatable. At least one of the top layer or the bottom layer may comprise flexible thin film material. At least some of the cells may be configured to collapse when negative pressure is applied to the collapsible sheet.
In some embodiments, at least one cell may have a hexagonal shape. The plurality of cells may have uniform size and shape, or at least some of the plurality of cells may have non-uniform size and/or shape. In some embodiments, the collapsible sheet may further comprise a cell wall. The cell wall may be inflatable. The collapsible sheet further comprises an indicator on one or more cells configured to indicate a direction where the collapsible sheet will collapse upon collapse of any particular cell.
In some embodiments, the collapsible sheet may be configured to cover the wound and form a seal around the wound. The wound closure device may further comprise a suction port configured to supply negative pressure to the wound and/or a tissue protection layer configured to be positioned over the wound below the collapsible sheet. The port may be integrated in the collapsible sheet. The port may comprise a valve including superabsorbent material configured to swell and at least partially close the valve when a rate of absorption of wound fluid is greater than a rate of evaporation of wound fluid. The bottom surface of the collapsible sheet may comprise one or more gaps between cells. The wound closure device may further comprise one or more drapes configured to cover the collapsible sheet and form a seal around the wound.
In certain embodiments, a method of treating a wound comprises placing the collapsible sheet over the wound. The method may further comprise applying or causing application of negative pressure through the collapsible sheet to the wound, wherein the application of negative pressure causes the collapsible sheet to collapse. The method may further comprise placing a tissue protection layer over the wound before placing the collapsible sheet.
Other embodiments of an apparatus for use with negative pressure, devices and associated methods are described below.
Embodiments disclosed in this section or elsewhere in this specification relate to apparatuses and methods of treating a wound with reduced pressure, including pump and wound dressing components and apparatuses. The apparatuses and components comprising the wound overlay and packing materials, if any, are sometimes collectively referred to in this section or elsewhere in this specification as dressings.
It will be appreciated that throughout this specification reference is made to a wound. It is to be understood that the term wound is to be broadly construed and encompasses open and closed wounds in which skin is torn, cut or punctured or where trauma causes a contusion, or any other superficial or other conditions or imperfections on the skin of a patient or otherwise that, in some cases, benefit from reduced pressure treatment. A wound is thus broadly defined as any damaged region of tissue where fluid may or may not be produced. Examples of such wounds include, but are not limited to, abdominal wounds or other large or incisional wounds, either as a result of surgery, trauma, sterniotomies, fasciotomies, or other conditions, dehisced wounds, acute wounds, chronic wounds, subacute and dehisced wounds, traumatic wounds, amputation wounds, flaps and skin grafts, lacerations, abrasions, contusions, burns, electrical burns, diabetic ulcers, pressure ulcers, stoma, surgical wounds, trauma and venous ulcers or the like.
As is used in this section or elsewhere in this specification, reduced or negative pressure levels, such as −X mmHg, represent pressure levels that are below standard atmospheric pressure, which typically corresponds to 760 mmHg (or 1 atm, 29.93 inHg, 101.325 kPa, 14.696 psi, etc.). Accordingly, a negative pressure value of −X mmHg reflects absolute pressure that is X mmHg below, for example, 760 mmHg or, in other words, an absolute pressure of (760−X) mmHg. In addition, negative pressure that is “less” or “smaller” than −X mmHg corresponds to pressure that is closer to atmospheric pressure (e.g., −40 mmHg is less than −60 mmHg). Negative pressure that is “more” or “greater” than −X mmHg corresponds to pressure that is further from atmospheric pressure (e.g., −80 mmHg is more than −60 mmHg).
The negative pressure range for some embodiments of the present disclosure can be approximately −80 mmHg, or between about −10 mmHg and −200 mmHg. Note that these pressures are relative to normal ambient atmospheric pressure. Thus, −200 mmHg would be about 560 mmHg in practical terms. In some embodiments, the pressure range can be between about −40 mmHg and −150 mmHg. Alternatively, a pressure range of up to −75 mmHg, up to −80 mmHg or over −80 mmHg can be used. Also in other embodiments a pressure range of below −75 mmHg can be used. Alternatively, a pressure range of over approximately −100 mmHg, or even −150 mmHg, can be supplied by the negative pressure apparatus. In some embodiments, the negative pressure range can be as small as about −20 mmHg or about −25 mmHg, which may be useful to reduce fistulas. In some embodiments of wound closure devices described here, increased wound contraction can lead to increased tissue expansion in the surrounding wound tissue. This effect may be increased by varying the force applied to the tissue, for example by varying the negative pressure applied to the wound over time, possibly in conjunction with increased tensile forces applied to the wound via embodiments of the wound closure devices. In some embodiments, negative pressure may be varied over time for example using a sinusoidal wave, square wave, and/or in synchronization with one or more patient physiological indices (e.g., heartbeat).
Examples of such applications where additional disclosure relating to the preceding descriptions may be found include U.S. Pat. No. 8,235,955, titled “Wound treatment apparatus and method,” issued Aug. 7, 2012 and U.S. Pat. No. 7,753,894, titled “Wound cleansing apparatus with stress,” issued Jul. 13, 2010. Both applications are hereby incorporated by reference in their entirety. Other applications that may contain teachings relevant for use with the embodiments described in this section or elsewhere in this specification may include application Ser. No. 12/886,088, titled “Systems And Methods For Using Negative Pressure Wound Therapy To Manage Open Abdominal Wounds,” filed Sep. 20, 2010, published as US 2011/0213287; application Ser. No. 13/092,042, titled “Wound Dressing And Method Of Use,” filed Apr. 21, 2011, published as US 2011/0282309; and application Ser. No. 13/365,615, titled “Negative Pressure Wound Closure Device,” filed Feb. 3, 2012, published as US 2012/0209227, the entireties of each of which are hereby incorporated by reference. Still more applications that may contain teachings relevant for use with the embodiments described in this specification are application Ser. No. 13/942,493, titled “Negative Pressure Wound Closure Device,” filed Jul. 15, 2013, published as US 2014/0180225; PCT App. No. PCT/US2013/050619, filed Jul. 16, 2013 titled “Negative Pressure Wound Closure Device,” published as WO 2014/014871 A1; PCT App. No. PCT/US2013/050698, filed Jul. 16, 2013 titled “Negative Pressure Wound Closure Device,” published as WO 2014/014922 A1; PCT App. No. PCT/IB2013/01555, titled “Devices and Methods for Treating and Closing Wounds with Negative Pressure,” filed May 5, 2013, published as WO 2013/175309 A1; PCT App. No. PCT/US2014/025059, titled “Negative Pressure Wound Closure Device and Systems and Methods of Use in Treating Wounds with Negative Pressure,” filed Mar. 12, 2014, published as WO 2014/165275 A1; PCT App. No. PCT/GB2014/050746, “Compressible Wound Fillers and Systems and Methods of Use In Treating Wounds With Negative Pressure,” filed Mar. 13, 2014, published as WO 2014/140578 A1; PCT App. No. PCT/US2014/061627, titled “Negative Pressure Wound Closure Device,” filed Oct. 21, 2014, and published as 2016/0287765 A1; and PCT App. No. PCT/US2016/029888, titled “Negative Pressure Wound Closure Device,” filed Apr. 28, 2016, published as WO 2016/176513. Each of the aforementioned applications is hereby incorporated by reference in its entirety and should be considered part of the present specification.
As used in this section or elsewhere in this specification, the term “horizontal,” when referring to a wound, indicates a direction or plane generally parallel to the skin surrounding the wound. The term “vertical,” when referring to a wound, generally refers to a direction extending perpendicular to the horizontal plane. The term “longitudinal,” when referring to a wound, generally refers to a direction in the horizontal plane taken in a direction along which the wound is longest. The term “lateral,” when referring to a wound, generally refers to a direction in the horizontal plane perpendicular to the longitudinal direction. The terms “horizontal,” “vertical,” “longitudinal,” and “lateral” may also be used to describe the collapsible sheets and wound closure devices described throughout this specification. When describing these structures or devices, these terms should not be construed to require that the structures or devices necessarily be placed into a wound in a certain orientation, though in certain embodiments, it may be preferable to do so.
In use, the wound 101 may be prepared and cleaned. In some cases, a non- or minimally-adherent tissue protection layer (not illustrated) may be applied over any exposed internal tissue. The wound 101 is then covered with wound closure device 104, optionally so as to form a fluid-tight seal. In some embodiments, the wound 101 and the wound closure device 104 further covered with the drape so as to form a fluid-tight seal. A first end of the conduit 108 is then placed in fluidic communication with the wound, for example via the aperture 106. The second end of the conduit 108 is connected to the pump 110. The pump 110 may then be activated so as to supply negative pressure to the wound 101 and evacuate wound exudate from the wound 101. As will be described in additional detail herein and in relation to the embodiments of the foregoing wound closure devices, negative pressure may also aid in promoting closure of the wound 101, for example by approximating opposing wound margins.
Any structure or component disclosed in this section or elsewhere in the specification may comprise a radiopaque material. A radiopaque material advantageously allows a clinician to more easily find pieces of the disclosed wound closure device that may have come loose from the structure and become lost in the wound. Some examples of radiopaque materials include barium sulfate, bismuth trioxide, bismuth subcarbonate, bismuth oxychloride, and tungsten.
A wound closure device as described in this section or elsewhere in the specification may include a collapsible sheet.
All collapsible sheets described in this section or elsewhere in the specification may be fashioned to accommodate any size of wound. However, to better accommodate the needs of the clinical environment, in certain embodiments, collapsible sheets described herein may be provided in a pack of two sizes, one smaller collapsible sheet and one larger collapsible sheet about 1.25 times as larger, about 1.5 times as large, about 1.75 times as large, about 2 times as larger, about 2.5 times as larger, about 3 times as large, about 4 times as large, about 5 times as large, or more than about 5 times as large. In some embodiments, the pack may comprise more than two sizes, such as three sizes, four sizes, five sizes, or more than five sizes. The collapsible sheet within the pack may be of a variety of sizes in relation to one another such as the ratios described herein. In some embodiments, a large collapsible sheet may be provided, such that it can be cut into a desirable size, or torn along an optional pre-cut.
Collapsible sheets described in this section or elsewhere in the specification, may be applied on the wound. In some embodiments, a tissue protection layer may be placed or positioned in and/or on the wound, before placement of the collapsible sheet. In some embodiments, the collapsible sheet may be adhered or sealed to the skin on the periphery of the wound so as to create a fluid-tight seal, and the negative pressure may be provided beneath the collapsible sheet. In some embodiments, the drape may be provided above the collapsible sheet and may be adhered or sealed to the skin on the periphery of the wound so as to create a fluid-tight seal, and the negative pressure may be provided beneath the drape and/or the collapsible sheet.
In certain embodiments, the collapsible sheet 200 can collapse in any manner described in this section or elsewhere in this specification with or without the application of negative pressure. For example, the collapsible sheet may collapse significantly more in one plane than in another plane, upon application of negative pressure. In some embodiments, the collapsible sheet may collapse more in a vertical plane parallel to the thickness of the collapsible sheet than in a horizontal plane parallel to the length and width of the collapsible sheet. In some embodiments, particular cells may collapse in a first direction, while another cells may collapse in the same or other direction. The collapsible sheet may be comprised of any materials described in this section or elsewhere in this specification, including one or more of flexible plastics such as silicone, polyurethane, rigid plastics such as polyvinyl chloride, semi-rigid plastics, semi-flexible plastics, biocompatible materials, composite materials, metals, and foam. In certain embodiments, the collapsible sheet may comprise a radio opaque material, to more readily allow a clinician to find pieces of the collapsible sheet within the wound.
Returning to
The collapsible sheet 200 may be made from one single material, such as those described elsewhere in the specification, or the collapsible sheet may be made from multiple materials. For example, cell walls 212 may be constructed from more rigid material while the top layer 202 and the bottom layer 204 may be constructed from more flexible material. The top layer 202 and the bottom layer 204 may have flat surface or uneven surface. In some embodiments, the top layer 202 and/or the bottom layer 204 may have embossed surface as cells 210 are bulged out on their top and/or bottom end. In some embodiments, the top layer 202 and/or the bottom layer 204 may be flat in their natural state, but constructed from flexible material such that cells 210 can be bulged out on their top and/or bottom end when cells are inflated.
The collapsible sheet 200 and all collapsible sheets and wound closure devices described in this section or elsewhere in this specification can collapse on a variety of timescales in a dynamic fashion. In certain embodiments, the majority of the collapse may occur within the first few minutes upon application of negative pressure. However, after the initial collapse, the collapsible sheet or wound closure device may continue to collapse at a much slower rate, thereby applying increasing tension over a long period of time and drawing the edges of the wound closer together. By slowly drawing the wound edges closer together over time, the collapsible sheet or wound closure device allows the surrounding healing tissue to remodel synergistically with the closure of the device or collapsible sheet. Slow, dynamic wound closure may allow the surrounding tissue to heal at an accelerated rate, because the collapsing sheet or device slowly brings the edges of the wound closer together without stressing the newly formed or weakened tissue too quickly.
In certain embodiments, up to 90% of the collapse of the collapsible sheet or wound closure device may occur within the first few minutes upon application of negative pressure, while the remaining 10% of the collapse may occur slowly over a period of many minutes, hours, days, weeks, or months. In other embodiments, up to about 80% of the collapse, up to about 70%, up to about 60%, up to about 50%, up to about 40%, up to about 30%, up to about 20%, up to about 10%, or about 0% of the collapse will occur within the first few minutes upon application of negative pressure while the remainder of the collapse occurs at a much slower rate such as over the course of many minutes, hours, days weeks, or months. In other embodiments, the collapsible sheet can collapse at a variable rate. In some embodiments, the entirety of the collapse occurs at a slowed rate, while in other embodiments the entirety of the collapse occurs almost immediately within the first few minutes. In further embodiments, the collapse can occur at any rate and the rate can vary over time. In certain embodiments, the rate of collapse can be altered in a variable fashion by adding and/or removing portions of the structure or by controlling the application of negative pressure and irrigant fluid.
In some embodiments, the collapsible sheet 200 may be inflatable. The collapsible sheet may be constructed from flexible film material, for example polyurethane, such that cells 210 may be filled with fluid, such as air, and inflated. In some embodiments, the collapsible sheet 200 is constructed from a top layer 202, a bottom layer 204, and optional cell walls 220 each constructed from flexible film material, for example polyurethane, and adhered to one another for example by adhesive, heat welding, radio frequency welding, laser welding, or ultrasonic welding. In some embodiments, each of the cells 210 of the collapsible sheet 200 is completely enclosed by the top layer 202, the bottom layer 204, and cell walls 220, such that space within each of the cell 210 is fludically isolated and inflated to maintain its shape unless the cell is punctured, like bubbles in bubble wraps. In embodiments of inflatable collapsible sheets, the top layer, the bottom layer and cell walls may be constructed from flexible film material which can withstand the fluid pressure within the inflated cell, such that cells do not burst without puncturing or cutting.
In some embodiments, the collapsible sheet 200 may include a valve or port, such that cells can be reversibly inflated. In addition to, or alternatively to the foregoing, collapsible sheets may have a mechanism that permits inflated cells to be sealed without manually closing the valve or port. For example, in some embodiments, a collapsible sheet includes one or more one-way or non-return valves at one or more junctions between the fluid channel (which can be an air channel) and a cell.
In some embodiments, the collapsible sheet 200 can be at least partially constructed from relatively rigid polymer materials, such that the collapsible sheet 200 and cells 210 can withstand greater strength and maintain its structure even without being inflated. While collapsible sheets constructed from more flexible and thinner material can be used for curved regions such as arms or legs, collapsible sheets constructed from more rigid collapsible sheets can be used in wider regions such as sacral regions. The collapsible sheet 200 can be constructed from both relatively flexible film materials and relatively rigid polymer materials. For example, in some embodiments, the top layer 202 and the bottom layer 204 are constructed from flexible film layers such that cells 210 can be inflated, while cell walls are constructed from more rigid materials to help the collapsible sheet 200 to maintain its structure.
Any of the collapsible sheets described in this section or elsewhere in the specification may be constructed using any suitable methods. For example, the collapsible sheets may be constructed via molding or may be printed directly using 3D printing technology. In certain embodiments, the collapsible sheets of
In some embodiments, the collapsible sheet 200 of
In some embodiments, the collapsible sheet 200 can be constructed from a transparent material such that the user of the collapsible sheet or the wound closure device can adjust the collapsible sheet relative to the wound, and monitor the wound or tissue beneath the collapsible sheet 200.
As described in elsewhere in the specification, the collapsible sheet 300 may collapse by collapsing one or more cells 310. When each of cells 310 is filled with, for example, air and/or each of cells are inflated, none of the cells 310 may collapse. In fact, cells 310 may expand in a negative pressure environment as the air pressure outside the cell would be lower than the pressure inside the cell. However, when one or more inflated cells 310 is deflated, for example by puncturing a hole 330 and exposing the interior volume of the cell to the exterior environment, the cell 310 may collapse with negative pressure as indicated by the arrows in
In some embodiments, the cell 310 may be collapsed by puncturing one or more holes 330 on the top layer 302 and/or the bottom layer 304 of the collapsible sheet 300. In some embodiments, cells may have one or more holes which can be reversibly open or closed. For example, as shown in
In some embodiments, one or more cells of collapsible sheets can be deflated by exposing cells to the negative pressure, or directly applying negative pressure to one or more cells, in addition to methods described in this section or elsewhere in the specification, such as puncturing or opening tabs. By directly applying negative pressure, one may deflate a cell of a collapsible sheet regardless of whether the cell is inflatable. For example, a non-inflatable collapsible sheet which is constructed from more rigid polymer material may collapse while such collapsible sheet may not substantially collapse from puncturing. Further, applying negative pressure directly to the cell may also facilitate collapse of the cell of the inflatable collapsible sheets and increase degree of collapse from its deflated state, such that facilitating greater closure of the wound.
Returning to
When different cells collapse in different directions, the direction of collapse may be visually indicated on the cell or tab for the convenience of a practitioner. For example, a tab similar with the detachable tab 420 of
As disclosed elsewhere in the specification, the negative pressure may be provided beneath the collapsible sheet 300. In some embodiments, such as shown in
In some embodiments, similarly with inflatable cells described in this section or elsewhere in the specification, any one of inflatable cell wall sections 520 may collapse. For example, inflatable cell wall sections 520 may collapse by being punctured, or being opened by removing detachable tabs such as tabs described in relation with
Additionally, collapsed inflatable cell wall sections may be less rigid than other inflatable cell wall sections which are not deflated. When cell(s) collapse, cell(s) may collapse more from being surrounded by more flexible cell walls than by more rigid cell walls. Accordingly, in some embodiments, cells 510 of the collapsible sheet 500 may collapse more from deflated cell wall sections than from inflated cell wall sections. In some embodiments, the practitioner or user of the collapsible sheet 500 may control the direction of collapse of each cells 510 and the collapsible sheet 500 overall, by selectively puncturing or opening the detachable tabs of inflatable cell wall sections 520. For example, the practitioner may deflate one, two, three, or more of the inflatable cell wall sections around a cell before or after the practitioner let the cell collapse. In some embodiments, such direction of collapse may be indicated in each inflatable cell wall sections, for example, by printing directional arrows on cell or tabs, color coding or numbering each inflatable cell wall, or any other mechanisms described elsewhere in the specification or suitable to help the practitioner to selectively deflating inflatable cell walls.
In some embodiments, the practitioner may deflate the inflatable cell wall sections 520 before deflating cells 510. In some embodiments, the practitioner may deflate the inflatable cell wall sections after deflating cells 510 as described in this section or elsewhere in the specification, for example, to further adjust direction and amount of collapse.
Certain wounds, such as fasciotomy wounds, often exude a lot of wound fluid. In such case, applying negative pressure beneath the collapsible sheet over certain wound area may exert too much stress on the wound from the collapse of the collapsible structure. A port similar with the port 650 of
Port systems 700a and 700b include a valve 750 and a conduit 760 configured to supply negative pressure. The port system 700a of
Although this disclosure describes certain embodiments, it will be understood by those skilled in the art that many aspects of the methods and devices shown and described in the present disclosure may be differently combined and/or modified to form still further embodiments or acceptable examples. All such modifications and variations are intended to be included herein within the scope of this disclosure. Indeed, a wide variety of designs and approaches are possible and are within the scope of this disclosure. No feature, structure, or step disclosed herein is essential or indispensable. Moreover, while illustrative embodiments have been described herein, the scope of any and all embodiments having equivalent elements, modifications, omissions, combinations (e.g., of aspects across various embodiments), substitutions, adaptations and/or alterations as would be appreciated by those in the art based on the present disclosure. While certain embodiments have been described, these embodiments have been presented by way of example only, and are not intended to limit the scope of protection.
Features, materials, characteristics, or groups described in conjunction with a particular aspect, embodiment, or example are to be understood to be applicable to any other aspect, embodiment or example described in this section or elsewhere in this specification unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The protection is not restricted to the details of any foregoing embodiments. The protection extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.
Furthermore, certain features that are described in this disclosure in the context of separate implementations can also be implemented in combination in a single implementation. Conversely, various features that are described in the context of a single implementation can also be implemented in multiple implementations separately or in any suitable subcombination. Moreover, although features may be described above as acting in certain combinations, one or more features from a claimed combination can, in some cases, be excised from the combination, and the combination may be claimed as a subcombination or variation of a subcombination.
Moreover, while operations may be depicted in the drawings or described in the specification in a particular order, such operations need not be performed in the particular order shown or in sequential order, or that all operations be performed, to achieve desirable results. Other operations that are not depicted or described can be incorporated in the example methods and processes. For example, one or more additional operations can be performed before, after, simultaneously, or between any of the described operations. Further, the operations may be rearranged or reordered in other implementations. Those skilled in the art will appreciate that in some embodiments, the actual steps taken in the processes illustrated and/or disclosed may differ from those shown in the figures. Depending on the embodiment, certain of the steps described above may be removed, others may be added. Furthermore, the features and attributes of the specific embodiments disclosed above may be combined in different ways to form additional embodiments, all of which fall within the scope of the present disclosure. Also, the separation of various system components in the implementations described above should not be understood as requiring such separation in all implementations, and it should be understood that the described components and systems can generally be integrated together in a single product or packaged into multiple products.
For purposes of this disclosure, certain aspects, advantages, and novel features are described herein. Not necessarily all such advantages may be achieved in accordance with any particular embodiment. Thus, for example, those skilled in the art will recognize that the disclosure may be embodied or carried out in a manner that achieves one advantage or a group of advantages as taught herein without necessarily achieving other advantages as may be taught or suggested herein.
Conditional language, such as “can,” “could,” “might,” or “may,” unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain embodiments include, while other embodiments do not include, certain features, elements, and/or steps. Thus, such conditional language is not generally intended to imply that features, elements, and/or steps are in any way required for one or more embodiments or that one or more embodiments necessarily include logic for deciding, with or without user input or prompting, whether these features, elements, and/or steps are included or are to be performed in any particular embodiment.
Conjunctive language such as the phrase “at least one of X, Y, and Z,” unless specifically stated otherwise, is otherwise understood with the context as used in general to convey that an item, term, etc. may be either X, Y, or Z. Thus, such conjunctive language is not generally intended to imply that certain embodiments require the presence of at least one of X, at least one of Y, and at least one of Z.
Language of degree used herein, such as the terms “approximately,” “about,” “generally,” and “substantially” as used herein represent a value, amount, or characteristic close to the stated value, amount, or characteristic that still performs a desired function or achieves a desired result. For example, the terms “approximately”, “about”, “generally,” and “substantially” may refer to an amount that is within less than 10% of, within less than 5% of, within less than 1% of, within less than 0.1% of, and within less than 0.01% of the stated amount. As another example, in certain embodiments, the terms “generally parallel” and “substantially parallel” refer to a value, amount, or characteristic that departs from exactly parallel by less than or equal to 15 degrees, 10 degrees, 5 degrees, 3 degrees, 1 degree, 0.1 degree, or otherwise.
The scope of the present disclosure is not intended to be limited by the specific disclosures of preferred embodiments in this section or elsewhere in this specification, and may be defined by claims as presented in this section or elsewhere in this specification or as presented in the future. The language of the claims is to be interpreted broadly based on the language employed in the claims and not limited to the examples described in the present specification or during the prosecution of the application, which examples are to be construed as non-exclusive.
This application is a continuation of U.S. application Ser. No. 16/622,773, filed Dec. 13, 2019, which is a U.S. national stage application of International Patent Application No. PCT/EP2018/065400, filed Jun. 11, 2018, which claims priority to U.S. Provisional Application No. 62/519,775 filed on Jun. 14, 2017, which is incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
2245909 | Helen et al. | Jun 1941 | A |
3194239 | Sullivan et al. | Jul 1965 | A |
3789851 | LeVeen | Feb 1974 | A |
4467805 | Fukuda | Aug 1984 | A |
4608041 | Nielsen | Aug 1986 | A |
4699134 | Samuelsen | Oct 1987 | A |
4815468 | Annand | Mar 1989 | A |
5176663 | Svedman et al. | Jan 1993 | A |
5264218 | Rogozinski | Nov 1993 | A |
5376067 | Daneshvar | Dec 1994 | A |
5409472 | Rawlings et al. | Apr 1995 | A |
5415715 | Delage et al. | May 1995 | A |
5423857 | Rosenman et al. | Jun 1995 | A |
5512041 | Bogart | Apr 1996 | A |
5562107 | Lavender et al. | Oct 1996 | A |
5584859 | Brotz | Dec 1996 | A |
5636643 | Argenta et al. | Jun 1997 | A |
5695777 | Donovan et al. | Dec 1997 | A |
5810750 | Buser | Sep 1998 | A |
6176868 | Detour | Jan 2001 | B1 |
6503208 | Skovlund | Jan 2003 | B1 |
6548727 | Swenson | Apr 2003 | B1 |
6566575 | Stickels et al. | May 2003 | B1 |
6685681 | Lockwood et al. | Feb 2004 | B2 |
6770794 | Fleischmann | Aug 2004 | B2 |
6787682 | Gilman | Sep 2004 | B2 |
6977323 | Swenson | Dec 2005 | B1 |
7004915 | Boynton et al. | Feb 2006 | B2 |
7144390 | Hannigan et al. | Dec 2006 | B1 |
7315183 | Hinterscher | Jan 2008 | B2 |
7351250 | Zamierowski | Apr 2008 | B2 |
7361184 | Joshi | Apr 2008 | B2 |
7438705 | Karpowicz et al. | Oct 2008 | B2 |
7494482 | Orgill et al. | Feb 2009 | B2 |
7615036 | Joshi et al. | Nov 2009 | B2 |
7622629 | Aali | Nov 2009 | B2 |
7625362 | Boehringer et al. | Dec 2009 | B2 |
7683667 | Kim | Mar 2010 | B2 |
7700819 | Ambrosio et al. | Apr 2010 | B2 |
7754937 | Boehringer et al. | Jul 2010 | B2 |
7779625 | Joshi et al. | Aug 2010 | B2 |
7815616 | Boehringer et al. | Oct 2010 | B2 |
7857806 | Karpowicz et al. | Dec 2010 | B2 |
7863495 | Aali | Jan 2011 | B2 |
7892181 | Christensen et al. | Feb 2011 | B2 |
7896856 | Petrosenko et al. | Mar 2011 | B2 |
7909805 | Weston | Mar 2011 | B2 |
7910789 | Sinyagin | Mar 2011 | B2 |
7931774 | Hall et al. | Apr 2011 | B2 |
7942866 | Radl et al. | May 2011 | B2 |
7951124 | Boehringer et al. | May 2011 | B2 |
7964766 | Blott et al. | Jun 2011 | B2 |
7976519 | Bubb et al. | Jul 2011 | B2 |
7976524 | Kudo et al. | Jul 2011 | B2 |
8030534 | Radl et al. | Oct 2011 | B2 |
8057447 | Olson et al. | Nov 2011 | B2 |
8062331 | Zamierowski | Nov 2011 | B2 |
8067662 | Aali et al. | Nov 2011 | B2 |
8070773 | Zamierowski | Dec 2011 | B2 |
8114126 | Heaton et al. | Feb 2012 | B2 |
8123781 | Zamierowski | Feb 2012 | B2 |
8142419 | Heaton et al. | Mar 2012 | B2 |
8172816 | Kazala, Jr. et al. | May 2012 | B2 |
8187237 | Seegert | May 2012 | B2 |
8188331 | Barta et al. | May 2012 | B2 |
8197467 | Heaton et al. | Jun 2012 | B2 |
8207392 | Haggstrom et al. | Jun 2012 | B2 |
8235955 | Blott et al. | Aug 2012 | B2 |
8246590 | Hu et al. | Aug 2012 | B2 |
8257328 | Augustine et al. | Sep 2012 | B2 |
8273105 | Cohen et al. | Sep 2012 | B2 |
8328776 | Kelch et al. | Dec 2012 | B2 |
8337411 | Nishtala et al. | Dec 2012 | B2 |
8353931 | Stopek et al. | Jan 2013 | B2 |
8357131 | Olson | Jan 2013 | B2 |
8376972 | Fleischmann | Feb 2013 | B2 |
8430867 | Robinson et al. | Apr 2013 | B2 |
8447375 | Shuler | May 2013 | B2 |
8454990 | Canada et al. | Jun 2013 | B2 |
8460257 | Locke et al. | Jun 2013 | B2 |
8481804 | Timothy | Jul 2013 | B2 |
8486032 | Seegert et al. | Jul 2013 | B2 |
8500776 | Ebner | Aug 2013 | B2 |
8608776 | Coward et al. | Dec 2013 | B2 |
8632523 | Eriksson et al. | Jan 2014 | B2 |
8673992 | Eckstein et al. | Mar 2014 | B2 |
8679080 | Kazala, Jr. et al. | Mar 2014 | B2 |
8679153 | Dennis | Mar 2014 | B2 |
8680360 | Greener et al. | Mar 2014 | B2 |
8708984 | Robinson et al. | Apr 2014 | B2 |
8721629 | Hardman et al. | May 2014 | B2 |
8746662 | Poppe | Jun 2014 | B2 |
8764732 | Hartwell | Jul 2014 | B2 |
8791315 | Lattimore et al. | Jul 2014 | B2 |
8791316 | Greener | Jul 2014 | B2 |
8802916 | Griffey et al. | Aug 2014 | B2 |
8821535 | Greener | Sep 2014 | B2 |
8945030 | Weston | Feb 2015 | B2 |
9044579 | Blott et al. | Jun 2015 | B2 |
9061095 | Adie et al. | Jun 2015 | B2 |
9180231 | Greener | Nov 2015 | B2 |
9408755 | Larsson | Aug 2016 | B2 |
9421132 | Dunn | Aug 2016 | B2 |
9655807 | Locke et al. | May 2017 | B2 |
9849023 | Hall et al. | Dec 2017 | B2 |
10143485 | Locke et al. | Dec 2018 | B2 |
11116669 | Gowans et al. | Sep 2021 | B2 |
11724020 | Hunt | Aug 2023 | B2 |
20010034499 | Sessions et al. | Oct 2001 | A1 |
20020077661 | Saadat | Jun 2002 | A1 |
20020161346 | Lockwood et al. | Oct 2002 | A1 |
20040162512 | Liedtke et al. | Aug 2004 | A1 |
20040267312 | Kanner et al. | Dec 2004 | A1 |
20050142331 | Anderson et al. | Jun 2005 | A1 |
20050267424 | Eriksson et al. | Dec 2005 | A1 |
20060020269 | Cheng | Jan 2006 | A1 |
20060058842 | Wilke et al. | Mar 2006 | A1 |
20060069357 | Marasco | Mar 2006 | A1 |
20060155260 | Blott et al. | Jul 2006 | A1 |
20060217795 | Besselink et al. | Sep 2006 | A1 |
20060271018 | Korf | Nov 2006 | A1 |
20070052144 | Knirck et al. | Mar 2007 | A1 |
20070104941 | Kameda et al. | May 2007 | A1 |
20070118096 | Smith et al. | May 2007 | A1 |
20070123973 | Roth et al. | May 2007 | A1 |
20070129660 | McLeod et al. | Jun 2007 | A1 |
20070149910 | Zocher | Jun 2007 | A1 |
20070185463 | Mulligan | Aug 2007 | A1 |
20070213597 | Wooster | Sep 2007 | A1 |
20070282309 | Bengtson et al. | Dec 2007 | A1 |
20080041401 | Casola et al. | Feb 2008 | A1 |
20080108977 | Heaton et al. | May 2008 | A1 |
20080243096 | Svedman | Oct 2008 | A1 |
20080275409 | Kane et al. | Nov 2008 | A1 |
20080306456 | Riesinger | Dec 2008 | A1 |
20090005716 | Abuzaina et al. | Jan 2009 | A1 |
20090099519 | Kaplan | Apr 2009 | A1 |
20090105670 | Bentley et al. | Apr 2009 | A1 |
20090204423 | DeGheest et al. | Aug 2009 | A1 |
20090299308 | Kazala, Jr. | Dec 2009 | A1 |
20090312685 | Olsen et al. | Dec 2009 | A1 |
20100022990 | Karpowicz et al. | Jan 2010 | A1 |
20100047324 | Fritz et al. | Feb 2010 | A1 |
20100081983 | Zocher et al. | Apr 2010 | A1 |
20100137775 | Hu et al. | Jun 2010 | A1 |
20100150991 | Bernstein | Jun 2010 | A1 |
20100160874 | Robinson et al. | Jun 2010 | A1 |
20100179515 | Swain et al. | Jul 2010 | A1 |
20100198128 | Turnlund et al. | Aug 2010 | A1 |
20100262106 | Hartwell | Oct 2010 | A1 |
20100280468 | Haggstrom et al. | Nov 2010 | A1 |
20100312159 | Aali et al. | Dec 2010 | A1 |
20110021965 | Karp et al. | Jan 2011 | A1 |
20110022082 | Burke et al. | Jan 2011 | A1 |
20110059291 | Boyce et al. | Mar 2011 | A1 |
20110066096 | Svedman | Mar 2011 | A1 |
20110082480 | Viola | Apr 2011 | A1 |
20110110996 | Schoenberger et al. | May 2011 | A1 |
20110112458 | Holm et al. | May 2011 | A1 |
20110178451 | Robinson et al. | Jul 2011 | A1 |
20110224631 | Simmons | Sep 2011 | A1 |
20110224632 | Zimnitsky et al. | Sep 2011 | A1 |
20110224634 | Locke et al. | Sep 2011 | A1 |
20110264138 | Avelar et al. | Oct 2011 | A1 |
20110270301 | Cornet et al. | Nov 2011 | A1 |
20110305736 | Wieland et al. | Dec 2011 | A1 |
20120016321 | Wu et al. | Jan 2012 | A1 |
20120029455 | Perez-Foullerat et al. | Feb 2012 | A1 |
20120059412 | Fleischmann | Mar 2012 | A1 |
20120130327 | Marquez Canada | May 2012 | A1 |
20120136326 | Croizat et al. | May 2012 | A1 |
20120136328 | Johannison et al. | May 2012 | A1 |
20120143113 | Robinson et al. | Jun 2012 | A1 |
20120172926 | Hotter | Jul 2012 | A1 |
20120191132 | Sargeant | Jul 2012 | A1 |
20120209226 | Simmons et al. | Aug 2012 | A1 |
20120209227 | Dunn | Aug 2012 | A1 |
20120253302 | Corley | Oct 2012 | A1 |
20120302979 | Locke et al. | Nov 2012 | A1 |
20130023842 | Song | Jan 2013 | A1 |
20130150813 | Gordon et al. | Jun 2013 | A1 |
20130190705 | Vess et al. | Jul 2013 | A1 |
20130197457 | Kazala, Jr. et al. | Aug 2013 | A1 |
20130204213 | Heagle et al. | Aug 2013 | A1 |
20130245527 | Croizat et al. | Sep 2013 | A1 |
20130325142 | Hunter et al. | Dec 2013 | A1 |
20130331757 | Belson | Dec 2013 | A1 |
20140094730 | Greener et al. | Apr 2014 | A1 |
20140163415 | Zaiken et al. | Jun 2014 | A1 |
20140249495 | Mumby et al. | Sep 2014 | A1 |
20140296805 | Arthur et al. | Oct 2014 | A1 |
20150065968 | Sealy et al. | Mar 2015 | A1 |
20150119837 | Thompson, Jr. et al. | Apr 2015 | A1 |
20150157758 | Blucher et al. | Jun 2015 | A1 |
20150190288 | Dunn et al. | Jul 2015 | A1 |
20150196431 | Dunn et al. | Jul 2015 | A1 |
20150216732 | Hartwell et al. | Aug 2015 | A1 |
20150320602 | Locke et al. | Nov 2015 | A1 |
20150374561 | Hubbard, Jr. et al. | Dec 2015 | A1 |
20160144085 | Melin et al. | May 2016 | A1 |
20160184496 | Jaecklein et al. | Jun 2016 | A1 |
20170065751 | Toth | Mar 2017 | A1 |
20170281838 | Dunn | Oct 2017 | A1 |
20200139025 | Robinson et al. | May 2020 | A1 |
20200188564 | Dunn | Jun 2020 | A1 |
20210146022 | Hunt | May 2021 | A1 |
Number | Date | Country |
---|---|---|
2012261793 | Jan 2013 | AU |
2012261793 | Nov 2014 | AU |
2013206230 | May 2016 | AU |
101112326 | Jan 2008 | CN |
101744688 | Jun 2010 | CN |
201519362 | Jul 2010 | CN |
102038575 | May 2011 | CN |
202568632 | Dec 2012 | CN |
103071197 | May 2013 | CN |
203408163 | Jan 2014 | CN |
2949920 | Mar 1981 | DE |
1320342 | Jun 2003 | EP |
2279016 | Feb 2011 | EP |
2567717 | Mar 2013 | EP |
2389794 | Dec 2003 | GB |
2423019 | Aug 2006 | GB |
2489947 | Oct 2012 | GB |
2496310 | May 2013 | GB |
S6257560 | Mar 1987 | JP |
2012105840 | Jun 2012 | JP |
62504 | Apr 2007 | RU |
1818103 | May 1993 | SU |
WO-0185248 | Nov 2001 | WO |
WO-0189392 | Nov 2001 | WO |
WO-0205737 | Jan 2002 | WO |
WO-03003948 | Jan 2003 | WO |
WO-03049598 | Jun 2003 | WO |
WO-2005046761 | May 2005 | WO |
WO-2005105174 | Nov 2005 | WO |
WO-2006046060 | May 2006 | WO |
WO-2008027449 | Mar 2008 | WO |
WO-2008064502 | Jun 2008 | WO |
WO-2008104609 | Sep 2008 | WO |
WO-2009112062 | Sep 2009 | WO |
WO-2010033725 | Mar 2010 | WO |
WO-2010097570 | Sep 2010 | WO |
WO-2011023384 | Mar 2011 | WO |
WO-2012082716 | Jun 2012 | WO |
WO-2012082876 | Jun 2012 | WO |
WO-2012136707 | Oct 2012 | WO |
WO-2012142473 | Oct 2012 | WO |
WO-2013012381 | Jan 2013 | WO |
WO-2013043258 | Mar 2013 | WO |
WO-2013071243 | May 2013 | WO |
WO-2013076450 | May 2013 | WO |
WO-2013079947 | Jun 2013 | WO |
WO-2013175309 | Nov 2013 | WO |
WO-2013175310 | Nov 2013 | WO |
WO-2014013348 | Jan 2014 | WO |
WO-2014014842 | Jan 2014 | WO |
WO-2014014871 | Jan 2014 | WO |
WO-2014140578 | Sep 2014 | WO |
WO-2014158526 | Oct 2014 | WO |
WO-2014165275 | Oct 2014 | WO |
WO-2014178945 | Nov 2014 | WO |
WO-2014194786 | Dec 2014 | WO |
WO-2015008054 | Jan 2015 | WO |
WO-2015061352 | Apr 2015 | WO |
WO-2015109359 | Jul 2015 | WO |
WO-2015110409 | Jul 2015 | WO |
WO-2015110410 | Jul 2015 | WO |
WO-2015169637 | Nov 2015 | WO |
WO-2015193257 | Dec 2015 | WO |
WO-2016018448 | Feb 2016 | WO |
WO-2016176513 | Nov 2016 | WO |
WO-2016179245 | Nov 2016 | WO |
WO-2017106576 | Jun 2017 | WO |
WO-2018038665 | Mar 2018 | WO |
WO-2018041805 | Mar 2018 | WO |
WO-2018044944 | Mar 2018 | WO |
WO-2018044949 | Mar 2018 | WO |
WO-2018085457 | May 2018 | WO |
WO-2018140386 | Aug 2018 | WO |
WO-2018237206 | Dec 2018 | WO |
Entry |
---|
“Definition of 3D Printer,” American Heritage Dictionary of the English Language, Fifth Edition, accessed on Feb. 22, 2018 from URL: https://www.thefreedictionary.com , 2016, 1 page. |
“Definition of Adhere,” The Free Dictionary, accessed on Mar. 23, 2017 from http://www.thefreedictionary.com/adhere, 6 pages. |
“Definition of Oculiform,” Webster's Revised Unabridged Dictionary, accessed from The Free Dictionary on May 30, 2018 from URL: https://www.thefreedictionary.com/Oculiform, 1913, 1 page. |
“Definition of Throughout,” Merriam-Webster Dictionary, accessed on Aug. 29, 2017 from https://www.merriam-webster.com/dictionary/throughout, 11 pages. |
Hougaard, et al., “The Open Abdomen: Temporary Closure with a Modified Negative Pressure Therapy Technique,” International Wound Journal, ISSN 1742-4801, 2014, pp. 13-16. |
International Preliminary Report on Patentability for Application No. PCT/EP2018/065400, dated Dec. 26, 2019, 10 pages. |
International Search Report and Written Opinion for Application No. PCT/EP2018/065400, dated Sep. 27, 2018, 12 pages. |
Jin S.G., et al., “Influence of Hydrophilic Polymers on Functional Properties and Wound Healing Efficacy of Hydrocolloid Based Wound Dressings,” Int J Pharm, Mar. 30, 2016, vol. 501 (1-2), pp. 160-166. |
Kapischke M., et al., “Self-Fixating Mesh for the Lichtenstein Procedure-a Prestudy,” Langenbeck's Arch Surg, 2010, vol. 395, pp. 317-322. |
Smith & Nephew Inc., “Negative Pressure Wound Therapy Clinical Guidelines,” Copyright 2013, 78 pages. |
U.S. Appl. No. 16/622,773, Collapsible Sheet for Wound Closure and Method of Use, filed Aug. 15, 2023. |
Number | Date | Country | |
---|---|---|---|
20230263951 A1 | Aug 2023 | US |
Number | Date | Country | |
---|---|---|---|
62519775 | Jun 2017 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16622773 | US | |
Child | 18141297 | US |